Literature DB >> 8418017

An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors.

S Chadha1, B R Rao, B J Slotman, C C van Vroonhoven, T H van der Kwast.   

Abstract

To visualize the heterogeneity of androgen receptor (AR) and progesterone receptor (PR) expression in ovarian tumors, 61 specimens were studied immunohistochemically using specific mouse monoclonal antibodies. The tested ovarian tumors included ovarian carcinomas of serous, mucinous, endometrioid, undifferentiated, and clear cell types as well as borderline epithelial tumors, mucinous cystadenomas, granulosa cell tumors, metastatic ovarian tumors, and one case of immature teratoma. Sixty-seven percent of ovarian carcinomas expressed AR, while 46% of the ovarian carcinomas expressed PR. In addition, the three tested borderline epithelial tumors were AR positive. Androgen receptor and PR were primarily localized in the nuclei of ovarian tumor cells. In three tumors focal staining of intervening stroma cells was observed. Interestingly, 35 of the granulosa cell tumors expressed PR as well as AR. All tumor types displayed a wide range in their proportions of AR- and PR-positive tumor cells. A poor correlation, however, was observed when semiquantitative immunohistochemical AR staining results on 17 ovarian carcinomas were compared with biochemical cytosol AR estimations using the dextran-coated charcoal method. Our study indicates that AR as well as PR is expressed by a substantial proportion of ovarian borderline and malignant tumors and that there is a strong heterogeneity in expression of AR and PR. It is possible to evaluate the prognostic significance of these receptors in ovarian cancers on fresh-frozen tumor specimens using a simple immunohistochemical technique.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418017     DOI: 10.1016/0046-8177(93)90067-q

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  23 in total

1.  Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses.

Authors:  H C van Doorn; C W Burger; P van der Valk; H M Bonfrèr
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Mei-Chiung Shih; Daniel W Cramer
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

4.  Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

Authors:  Allison C Sharrow; Brigitte M Ronnett; Christopher J Thoburn; James P Barber; Robert L Giuntoli; Deborah K Armstrong; Richard J Jones; Allan D Hess
Journal:  J Ovarian Res       Date:  2010-03-31       Impact factor: 4.234

5.  Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival.

Authors:  Björn Nodin; Nooreldin Zendehrokh; Jenny Brändstedt; Elise Nilsson; Jonas Manjer; Donal J Brennan; Karin Jirström
Journal:  J Ovarian Res       Date:  2010-06-17       Impact factor: 4.234

6.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

Review 7.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

8.  Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Jessica Nearman; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

Review 9.  A Review of Principal Studies on the Development and Treatment of Epithelial Ovarian Cancer in the Laying Hen Gallus gallus.

Authors:  Purab Pal; Kara Nicole Starkweather; Karen Held Hales; Dale Buchanan Hales
Journal:  Comp Med       Date:  2021-07-29       Impact factor: 0.982

10.  E-cadherin expression and bromodeoxyuridine incorporation during development of ovarian inclusion cysts in age-matched breeder and incessantly ovulated CD-1 mice.

Authors:  Jean S Fleming; H James McQuillan; Melanie J Millier; Clare R Beaugié; Vicki Livingstone
Journal:  Reprod Biol Endocrinol       Date:  2007-04-11       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.